|
New
Strategies for the
Management of Diabetes:
Insulin
Analogs and Premixed Insulin Analogs
A
Continuing Education Monograph for Pharmacists, Nurses, and
Dietitians
Please
read the following information and select the appropriate link
at the bottom of the page to continue.
Target
Audience: This activity has been designed to meet
the educational needs of pharmacists, nurses, and dietitians
involved with the management of patients with diabetes.
Goal:
To provide healthcare professionals with a summary
of the development, efficacy and safety of insulin analogs and
premixed insulin analogs and a general guide for the proper
clinical use of these products.
Educational
Objectives: After reading this monograph, the participant
should be able to:
- Explain
the key pharmacokinetic considerations of insulin therapy
that were addressed in the development of insulin analogs.
- Describe
the molecular alterations of insulin analogs.
- State
the major pharmacokinetic differences between human insulin
and insulin analogs.
- Describe
the outcomes of two clinical trials showing safety and efficacy
of analogs and premixed insulin analogs.
- Identify
major considerations when individualizing treatment with insulin
analogs.
 |
Pharmacists:
The American Association of Diabetes Educators and Novo
Nordisk Pharmaceuticals, Inc. are accredited by the American
Council on Pharmaceutical Education (ACPE) as providers
of continuing pharmaceutical education. This program provides
1.0 contact hours (0.1 CEUs) of continuing education credit.
ACPE Universal Program Number 069-360-03-858-H01. |
 |
Registered
Nurses: The American Association of Diabetes
Educators
(AADE) is accredited as an approver of continuing education
in nursing by
the American Nurses Credentialing Center's Commission on
Accreditation.
This program, approval number 0203-071, is accredited by
1.2 contact hours.
|
 |
Dietitians:
American Association of Diabetes Educators (AM001)
is a Continuing Professional Education (CPE) Accredited
Provider with the Commission on Dietetic Registration
(CDR) from June 1, 2003 to May 31, 2006. Registered dietitians
(RD) and dietetic technicians, registered (DTR) will receive
1.0 Continuing Professional Education Unit (CPEU) for
completion of this program. Continuing Professional Education
Provider Accreditation does not constitute endorsement
by CDR of a provider, program, or materials.
|
Initial
Release Date: 05/21/2003
Planned Expiration Date: 05/21/2005
To
receive a statement of credit, you must:
- Successfully
complete the post-test (70% or better).
- Complete
the program evaluation.
Your statement
of credit will be issued immediately upon successful completion
of the test and submission of the evaluation form. The statement
of credit specific to your discipline will appear on your screen
and you will be given the option to print it for your files.
No additional statement of credit will be issued.
Editorial
Review Board:
Arturo
Rolla, MD
Assistant Clinical Professor of Medicine
Harvard Medical School and Tufts University
School of Medicine
Boston, MA
Condit
Steil, PharmD, CDE
Associate Professor of Pharmacy Practice and
Director, Center for Advancement of Pharmaceutical Care
Development in Community Practice
Samford University, McWhorter School of Pharmacy
Birmingham, AL
Deborah
Hinnen, ARNP, BC-ADM, CDE
Manager, Diabetes Services
Via Christi Regional Medical Center
Wichita, KS
Melinda
Maryniuk, RD, MEd, CDE
Program Manager, Special Services
Joslin Diabetes Center
Boston, MA
Fee:
There is no fee to receive credits for this continuing education
activity.
Commercial
Supporter: Written and funded with the support of
Novo Nordisk Pharmaceuticals, Inc., an ACPE accredited provider;
this program has been accredited by AADE for pharmacists, nurses,
and dietitians.
Trademarks:
Novolin,
NovoLog, Lente, Ultralente, Velosulin, NovoPen, Innovo, and
FlexPen are registered trademarks of Novo Nordisk A/S.
InDuo
is a registered trademark of LifeScan, Inc.
Humalog
and Humulin are registered trademarks of Eli Lilly and Company.
Mix
75/25 is a trademark of Eli Lilly and Company.
Lantus
is a registered trademark of Aventis Pharmaceuticals.
Faculty
Disclosure Statements: It is the policy of the American
Association of Diabetes Educators and Novo Nordisk Pharmaceuticals,
Inc. to ensure independence, balance, scientific rigor, and
integrity in all of their continuing education activities. The
faculty must disclose to the participants any significant relationships
with the commercial companies whose products or devices may
be mentioned in the monograph or with the commercial supporter
of this continuing education activity. The information is for
participant information only; it is not assumed that these relationships
will have a negative impact on the content of the activity.
Following are disclosure statements made by the Editorial Review
Board.
Arturo
Rolla, MD has disclosed that he has participated as a consultant
and speaker for Novo Nordisk Pharmaceuticals, Inc.
Condit
Steil, PharmD, CDE has disclosed that he has been a consultant
for Amylin, Aventis, and Novo Nordisk Pharmaceuticals, Inc.,
and has participated in the speaker's bureau for Eli Lilly and
Company and Aventis.
Deborah
Hinnen, ARNP, BC-ADM, CDE has disclosed that she has been
a consultant for Eli Lilly and Company, and has participated
in the speaker's bureau for Aventis and Eli Lilly and Company.
Melinda
Maryniuk, RD, MEd, CDE disclosed she has no relationships
with commercial entities related to the information presented
in the publication.
Disclosure
of Unlabeled Use:
This educational
activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The American
Association of Diabetes Educators and Novo Nordisk Pharmaceuticals,
Inc. do not recommend the use of any agent outside of the labeled
indications. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications,
and warnings.
Disclaimers:
The approval of this educational offering by AADE does not imply
endorsement of specific therapies, treatments, or products discussed
in the presentation.
The author, sponsor, and publisher of this continuing education
program have made all reasonable efforts to ensure that information
contained herein is accurate in accordance with the latest available
scientific knowledge at the time of accreditation of this continuing
education program. Information regarding drugs (e.g., their administration,
dosages, contraindications, adverse reactions, interactions, special
warnings, precautions) and drug delivery systems is subject to
change, however, and the reader is advised to check the manufacturer's
package insert for information concerning recommended dosage and
potential problems or cautions prior to dispensing or administering
the drug or using the drug delivery systems.
Click
the appropriate profession to continue to the activity:
Pharmacists
click here
Nurses
click here
Dietitians
click here
Other
Healthcare Professionals click here
Copyright
© 2003 Novo Nordisk Pharmaceuticals, Inc. All rights reserved.
126591
|
